Pharmacogenomics

Core Idea

Pharmacogenomics studies how genetic variation affects drug response — efficacy, dosing, and adverse reactions. Variants in drug-metabolizing enzymes (CYP2D6, CYP2C19), drug transporters (ABCB1), and drug targets (VKORC1 for warfarin, HLA alleles for hypersensitivity) explain much of the inter-individual variability in drug response. Clinical pharmacogenomics translates these findings into genotype-guided prescribing: patients are genotyped for relevant variants, and drug choice or dose is adjusted accordingly. Guidelines from CPIC (Clinical Pharmacogenetics Implementation Consortium) provide evidence-based recommendations for over 100 drug-gene pairs.

How It's Best Learned

Trace the warfarin dosing example end-to-end: examine how CYP2C9 and VKORC1 genotypes affect warfarin metabolism and sensitivity, calculate a genotype-adjusted dose using the IWPC algorithm, and compare to the standard one-size-fits-all dosing approach. Then examine the pharmacogenomic landscape of a commonly prescribed drug (e.g., clopidogrel/CYP2C19) and review the CPIC guideline.

Common Misconceptions

• Pharmacogenomics does not mean every drug needs genetic testing — only drug-gene pairs with strong evidence and actionable clinical recommendations warrant routine genotyping.
• A "poor metabolizer" genotype does not always mean the drug will not work — for prodrugs (like clopidogrel, which requires CYP2C19 activation), poor metabolizers have reduced efficacy; for drugs metabolized to inactive forms, poor metabolizers may have increased drug exposure and toxicity.

Explainer

The observation that patients respond differently to the same drug has been a persistent problem in medicine. Some patients achieve therapeutic benefit at standard doses while others experience severe adverse reactions or no benefit at all. Pharmacogenomics provides a molecular explanation: genetic variants in drug-metabolizing enzymes, transporters, targets, and immune molecules account for a large fraction of this variability. Understanding these variants enables precision prescribing — choosing the right drug at the right dose for each patient based on their genotype.

The most clinically important pharmacogenes are the cytochrome P450 enzymes — a family of liver enzymes that metabolize approximately 75% of all drugs. CYP2D6 alone metabolizes about 25% of drugs in clinical use, including codeine, tamoxifen, many antidepressants, and several antipsychotics. CYP2D6 is highly polymorphic, with alleles ranging from nonfunctional (no enzyme activity) to gene duplications (ultrarapid metabolism). The population distribution of these alleles varies by ancestry: CYP2D6 ultrarapid metabolizers are more common in East African and Middle Eastern populations (~10-30%) than in Europeans (~1-2%). CYP2C19 affects clopidogrel (an antiplatelet drug critical after cardiac stenting), where poor metabolizers have reduced drug activation and increased risk of stent thrombosis.

Beyond metabolism, genetic variation in drug targets directly affects efficacy. VKORC1 variants alter warfarin sensitivity by modifying the drug's target enzyme, with common variants explaining ~25% of dose variability. HLA alleles (particularly HLA-B*57:01 and HLA-B*15:02) mediate severe immune-mediated adverse drug reactions — abacavir hypersensitivity and carbamazepine-induced Stevens-Johnson syndrome, respectively. Pre-prescription HLA genotyping for these drugs has become standard of care in many settings, preventing potentially fatal adverse reactions.

The clinical implementation of pharmacogenomics is coordinated by CPIC, which publishes evidence-based guidelines translating genotype results into prescribing actions. For each drug-gene pair, CPIC defines metabolizer phenotype categories (poor, intermediate, normal, rapid, ultrarapid), assigns specific dosing or drug-choice recommendations for each category, and grades the evidence strength. Major health systems (St. Jude, Vanderbilt, Mayo Clinic) now implement preemptive pharmacogenomic testing — genotyping patients for panels of pharmacogenes before any specific drug is prescribed, storing the results in the medical record, and triggering clinical decision support alerts when a relevant drug is prescribed. This proactive approach avoids the delay of reactive testing and positions pharmacogenomics as a routine component of clinical care.